Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease

World J Gastroenterol. 2014 Aug 7;20(29):10108-14. doi: 10.3748/wjg.v20.i29.10108.

Abstract

Aim: To investigate a simple noninvasive scoring system for predicting liver cirrhosis in nonalcoholic fatty liver disease (NAFLD) patients.

Methods: A total of 1048 patients with liver-biopsy-confirmed NAFLD were enrolled from nine hepatology centers in Japan (stage 0, 216; stage 1, 334; stage 2, 270; stage 3, 190; stage 4, 38). The weight and height of the patients were measured using a calibrated scale after requesting the patients to remove their shoes and any heavy clothing. Venous blood samples were obtained in the morning after the patients had fasted overnight for 12 h. Laboratory evaluation was performed in all patients. Statistical analysis was conducted using SPSS version 12.0. Continuous variables were expressed as mean ± SD.

Results: The optimal cutoff value of platelet count, serum albumin, and aminotransferase/alanine aminotransferase ratio (AAR) was set at < 15.3 10(4)/μL, < 4.0 g/dL, and > 0.9, respectively, by the receiver operating characteristic curve. These three variables were combined in an unweighted sum (platelet count = 1 point, serum albumin = 1 point, AAR = 1 point) to form an easily calculated composite score for predicting cirrhosis in NAFLD patients, called the PLALA (platelet, albumin, AAR) score. The diagnosis of PLALA ≥ 2 had sufficient accuracy for detecting liver cirrhosis in NAFLD patients.

Conclusion: The PLALA score may be an ideal scoring system for detecting cirrhosis in NAFLD patients with sufficient accuracy and simplicity to be considered for clinical use.

Keywords: Alanine aminotransferase ratio; Albumin; Cirrhosis; Fibrosis; Nonalcoholic fatty liver disease; Platelet.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Alanine Transaminase / blood
  • Area Under Curve
  • Aspartate Aminotransferases / blood
  • Biomarkers / blood
  • Biopsy
  • Chi-Square Distribution
  • Clinical Enzyme Tests
  • Diagnosis, Differential
  • Female
  • Humans
  • Japan
  • Liver / pathology
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / diagnosis*
  • Liver Cirrhosis / etiology*
  • Logistic Models
  • Male
  • Mass Screening* / methods
  • Middle Aged
  • Multivariate Analysis
  • Non-alcoholic Fatty Liver Disease / blood
  • Non-alcoholic Fatty Liver Disease / complications*
  • Non-alcoholic Fatty Liver Disease / diagnosis*
  • Odds Ratio
  • Platelet Count
  • Predictive Value of Tests
  • ROC Curve
  • Risk Assessment
  • Risk Factors
  • Serum Albumin / analysis
  • Serum Albumin, Human
  • Severity of Illness Index

Substances

  • ALB protein, human
  • Biomarkers
  • Serum Albumin
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Serum Albumin, Human